IndustryCompany release
OXB confirms manufacturing deal with Aura Biosciences for bel-sar Phase 3 and commercial supply
OXB · Tue 17 Nov 2026
The UK cell and gene therapy CDMO will support late-stage development and manufacture of Aura's virus-like drug conjugate for ocular cancers, with potential commercial supply in view.
OXB, the UK-based cell and gene therapy contract development and manufacturing organisation (CDMO), confirmed on 17 November 2026 that it has a manufacturing and supply partnership with Aura Biosciences.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release: OXB ↗
Article written by VigiEye from the official source (OXB). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
Prenetics Global Ltd (PRE) · Wed 18 Nov 2026
Quantum-Si detects all 20 amino acids at single-molecule level on Proteus platform
🇺🇸 Quantum-Si Inc (QSI) · Wed 18 Nov 2026
NeOnc to meet FDA in January 2027 on NEO100 accelerated approval path
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
newcleo plc (NWCL) · Wed 18 Nov 2026
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026
Interpace Biosciences Q3 revenue rises 18% to $10.4M on thyroid testing growth
🇺🇸 Interpace Biosciences, Inc. (IDXG) · Tue 17 Nov 2026